meth-ill-FEN-i-date
REMS
Contraindicated in:
Use Cautiously in:
History of substance use
;Continual use (may produce psychological dependence or physical addiction)
;CV: hypertension, palpitations, tachycardia, hypotension, peripheral vasculopathy, SUDDEN DEATH
Derm: contact sensitization (erythema, edema, papules, vesicles) (transdermal), erythema, loss of skin pigmentation (transdermal), rash
EENT: blurred vision, ↑intraocular pressure, teeth grinding
GI: anorexia, constipation, cramps, diarrhea, dry mouth, metallic taste, nausea, vomiting
GU: priapism
MS: RHABDOMYOLYSIS
Neuro: hyperactivity, insomnia, restlessness, tremor, akathisia, behavioral disturbances, dizziness, dyskinesia, hallucinations, headache, irritability, mania, thought disorder, tics, Tourette syndrome
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA),
physical dependence
,psychological dependence
, toleranceDrug-drug:
Drug-Natural Products:
Drug-Food:
Attention-Deficit Hyperactivity Disorder
Narcolepsy
methylphenidate (oral): Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Jornay PM, Metadate CD, Methylin, Quillichew ER, Quillivant XR, Relexxii, Ritalin, Ritalin LA,
methylphenidate (transdermal): Daytrana
Absorption: Slow and incomplete after oral administration; absorption of sustained or extended-release tablet (ER) is delayed and provides continuous release; well absorbed from skin. Aptensio XR, Concerta, Relexxii, Ritalin LA: Provides initial rapid release followed by a second continuous release (biphasic release).
Distribution: Unknown.
Half-Life: 2–4 hr.
(CNS stimulation)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | unknown | 1–3 hr | 4–6 hr |
| PO-ER | unknown | 4–7 hr | 3–12 hr‡ |
| Transdermal | unknown | unknown | 12 hr |
‡Depends on formulation.
Advise patient that methylphenidate is a drug with known potential for abuse, misuse, and/or addiction. Store in safe place, protect it from theft, and never give to anyone other than the individual for whom it was prescribed.
NDC Code
